Table 2.
Slope analysis of eGFR (change per week, ml min−1 [1.73 m]−2)
| Population | Treatment (N/n) | Duration, weeks | Slope (95% CI) | Slope difference (95% CI) vs non-ertugliflozin | p valuea |
|---|---|---|---|---|---|
| Overall | Non-ertugliflozin (644) | 0–6 | −0.10 (−0.32, 0.13) | ||
| Ertugliflozin 5 mg (652) | −0.38 (−0.61, −0.15) | −0.29 (−0.61, 0.04) | 0.08 | ||
| Ertugliflozin 15 mg (640) | −0.45 (−0.68, −0.21) | −0.35 (−0.68, −0.02) | 0.04 | ||
| Non-ertugliflozin (630) | 6–104 | −0.01 (−0.02, 0.00) | |||
| Ertugliflozin 5 mg (633) | 0.02 (0.01, 0.03) | 0.03 (0.02, 0.04) | <0.001 | ||
| Ertugliflozin 15 mg (617) | 0.03 (0.02, 0.04) | 0.05 (0.04, 0.06) | <0.001 | ||
| UACR <3.39 mg/mmol at baseline | Non-ertugliflozin (489) | 0–6 | −0.07 (−0.32, 0.18) | ||
| Ertugliflozin 5 mg (490) | −0.37 (−0.62, −0.12) | −0.30 (−0.65, 0.06) | 0.10 | ||
| Ertugliflozin 15 mg (502) | −0.37 (−0.62, −0.12) | −0.30 (−0.65, 0.05) | 0.10 | ||
| Non-ertugliflozin (477) | 6–104 | −0.01 (−0.02, 0.00) | |||
| Ertugliflozin 5 mg (475) | 0.02 (0.01, 0.03) | 0.03 (0.02, 0.05) | <0.001 | ||
| Ertugliflozin 15 mg (487) | 0.04 (0.03, 0.05) | 0.05 (0.03, 0.06) | <0.001 | ||
| UACR ≥3.39 mg/mmol at baseline | Non-ertugliflozin (142) | 0–6 | −0.17 (−0.67, 0.33) | ||
| Ertugliflozin 5 mg (147) | −0.45 (−0.95, 0.04) | −0.28 (−0.98, 0.43) | 0.44 | ||
| Ertugliflozin 15 mg (126) | −0.61 (−1.15, −0.07) | −0.44 (−1.18, 0.30) | 0.25 | ||
| Non-ertugliflozin (140) | 6–104 | −0.03 (−0.05, −0.01) | |||
| Ertugliflozin 5 mg (143) | 0.00 (−0.02, 0.02) | 0.03 (0.00, 0.06) | 0.05 | ||
| Ertugliflozin 15 mg (118) | 0.01 (−0.01, 0.03) | 0.04 (0.01, 0.07) | 0.01 |
aTesting the slope difference between the ertugliflozin and non-ertugliflozin groups